Good Vita / The learning library

AOD-9604

A compound discussed in peptide marketing about body composition.

Educational information only. No medical advice or treatment recommendations.

← Back to the full library

Research compounds Human trial assessment Metabolic health

Also discussed as: AOD9604

What it is and how it works

AOD-9604 is a modified fragment related to the C-terminal region of human growth hormone, developed around hypotheses about fat metabolism. A fragment can have different properties from the full hormone; the parent molecule’s reputation does not establish the fragment’s clinical effects.

Source for the mechanism context →

A closer look at the cited evidence

Human trial assessment

This label describes the selected source below. It is not a complete ranking of the literature, a safety score, or an approval status.

Study or assessment
FDA — 2024 AOD-9604 briefing, effectiveness assessment
Design
FDA assessment of available clinical information, including a randomized, placebo-controlled obesity study.
Who or what was studied
The OPTIONS study enrolled 536 adults with obesity, of whom 502 were randomized.
What was observed
FDA reports no significant weight-loss difference at the primary endpoint between oral AOD-9604 and placebo.
Limits of interpretation
FDA notes limited published methodological detail. Oral trial findings do not establish effectiveness for injectable or transdermal products.
Read the cited study or assessment →

What the evidence means

Online fat-loss claims are not a substitute for controlled human outcome evidence.

Approval and regulatory context

This entry concerns an experimental compound, not an FDA-approved weight-management medicine.

Safety and uncertainty

Human safety information is limited.

What remains uncertain

A disappointing clinical result should remain visible alongside the proposed mechanism. Claims that a different delivery route solves the evidence gap require their own well-designed human studies, rather than an assumption.

These summaries are introductory and are not a complete account of the literature, adverse effects, contraindications, or interactions. Absence of a listed risk does not mean absence of risk. Different compounds, formulations, and routes cannot be treated as interchangeable.

Sources behind this overview

Read the source in its full context. Source links support the overview; they do not imply endorsement of this library by the source organization.

Start Your Assessment